Litifilimab (Biosimilar Reference Antibody) (CLEC4C)
Litifilimab (Biosimilar Reference Antibody) (CLEC4C)
Litifilimab (Biosimilar Reference Antibody) (CLEC4C)-RA0145-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
ELISA plate pre-coated Antigen protein, can bind Litifilimab (Biosimilar Reference Antibody) (CLEC4C)-RA0145 in a linear range of 3.91–31 ng/mL.
Litifilimab (Biosimilar Reference Antibody) (CLEC4C)

Catalog: 

RA0145

Target

CLEC4C

Isotype

IgG1 - kappa

Applications

ELISA;FC;Functional Assays;IF

Reactivities

Human

Size (＄)：

100 μg-50;1 mg-210;5 mg-500;10 mg-800;25 mg-1750;50 mg-3000;100 mg-4600

Data Sheet

Material Safety Data Sheet

Certificate of Analysis

Product Description

Litifilimab (also known as BIIB-059) is an investigational, humanized monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2), a receptor exclusively expressed on plasmacytoid dendritic cells (pDCs). By binding to BDCA2, litifilimab triggers the internalization and downregulation of the receptor, leading to the inhibition of pDC activation and the subsequent reduction of type I interferon (IFN) production. Since pDCs are a major source of pathogenic type I IFN in systemic lupus erythematosus (SLE) and other autoimmune diseases, this mechanism aims to dampen a key driver of autoimmunity. It is being clinically evaluated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Synonyms

BIIB-059, BIIB 059, BIIB059

CAS

2407378-48-5

Isotype

IgG1 - kappa

Host

Humanised

Target

CLEC4C

Reactivity

Human

Expression System

CHO

Applications

ELISA, FC, Functional Assays, IF; Recommended dilution: FC, IF:1:200

Purity

>98% by SDS-PAGE

Concentration

Bottled at the concentration indicated on the vial.

Buffer

0.01M PBS, pH 7.4, contains no stabilizers or preservatives.

Endotoxin

<1.0 EU/mg as determined by LAL method

Conjugation

Non-conjugated

Formulation

Liquid or Lyophilized powder Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

store at -20°C or -80°C. Avoid repeated freeze.

Type

Antibody

Purposes

For research use only

References 1

Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32(5):345-353.

References 2

Furie RA, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022 Sep 8;387(10):894-904.

References 3

References 4

References 5

Product Citations 1

Product Citations 2

https://pubmed.ncbi.nlm.nih.gov/37148249/
https://pubmed.ncbi.nlm.nih.gov/36069871/
https://www.oursmab.com/News/The-therapeutic-target-of-systemic-lupus-erythematosus-BDCA2.html

Target Description

Synonyms

C-type lectin domain family 4 member C, CLECSF11, CLECSF7, HECL, DLEC, BDCA2, CD303

Biology Area

Immunology;Innate Immunity;CD Markers

Function

Blood dendritic cell antigen 2 (BDCA2, also known as CD303 or CLEC4C) is a C-type lectin receptor that is specifically and highly expressed on the surface of human plasmacytoid dendritic cells (pDCs). pDCs are specialized immune cells that rapidly produce massive amounts of type I interferons (IFN-α/β) in response to viral nucleic acids or self-nucleic acids in autoimmune settings. Ligation of BDCA2 by an antibody like litifilumab initiates an inhibitory signaling cascade (via ITAM-bearing FcεRγ) that suppresses pDC activation, Toll-like receptor (TLR) 7 and 9 signaling, and the production of type I IFNs and other inflammatory cytokines. This makes BDCA2 an attractive target for selectively modulating pDC activity in interferon-driven autoimmune diseases.

Additional Articles 1

The-therapeutic-target-of-systemic-lupus-erythematosus-BDCA2

Additional Articles 2

Related Products

Anti-Human CD274/PDL1/B7H1 Antibody (22C3)

Catalog: 

RA0145

Target：

CD274/PDL1/B7H1

Isotype：

IgG - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Odesivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0145

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Porgaviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0145

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Enokizumab (Biosimilar Reference Antibody) (IL9)

Catalog: 

RA0145

Target：

IL9

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Bapotulimab (Biosimilar Reference Antibody) (ILDR2)

Catalog: 

RA0145

Target：

ILDR2

Isotype：

IgG2 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Atoltivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0145

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Tocilizumab (Biosimilar Reference Antibody) (IL6R)

Catalog: 

RA0145

Target：

IL6R/CD126

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Cosfroviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0145

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Bempikibart (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0145

Target：

IL7R/CD127

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Maftivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0145

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus

Contact Us

Send your request

Talk to us 

Get a quotation, discuss your requirement, receive advises from our antibody experts without obligation.